Minipooled-IVIG in Primary Immunodeficiency Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

15 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-01-01

Study Completion Date

2020-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. study the pharmacokinetics of mini-pooled intravenous immunoglobulin( MP-IVIG)
2. Study the safety and efficacy of a newly developed preparation of MP-IVIG in children with primary immunodeficiency (PID) :

* Adverse reaction of MP-IVIG(anaphylaxis and haemolysis)( no or mild or moderate)
* Prevention of severe bacterial infection
* Improvement of general health(weight gain and mentality)
* Integration in to social live
3. Compare the efficacy of MP-IVIG to standard IVIG in children with primary immunodeficiency (PID).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Inbon Errors of Immunity Attending Assiut University Children&Amp;#39;s Hospital: a Single Center Study

NCT06649643

Primary Immunodeficiency Diseases (PID)

NOT_YET_RECRUITING

Efficacy, Safety and Pharmacokinetic of Virchow IVIG in PID Patients

NCT07017036

Primary Immunodeficiency Diseases (PID)

NOT_YET_RECRUITING PHASE3

Evaluation of the Safety and Efficacy of Standard Intravenous Immunoglobulins in Pregnant Women With Primary Cytomegalovirus Infection

NCT01659684

Cytomegalovirus Congenital Infection

UNKNOWN NA

Transfusion-Transmitted Cytomegalovirus Prevention in Neonates

NCT00000584

Blood Transfusion Cytomegalovirus Infections

COMPLETED PHASE3

A Retrospective, Blinded Validation of a Host-response Based Diagnostics

NCT01911143

Fever Respiratory Tract Infections Urinary Tract Infections +2 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary immunodeficiency diseases (PID) are a heterogeneous group of inherited disorders of the immune system, predisposing individuals to recurrent infections, allergy, autoimmunity, and malignancies. Clinical descriptions have already been made for more than 200 PIDs, for which over 150 forms of PID have been molecularly characterized .

A population prevalence of diagnosed PID in the United States at approximately 1 in 1,200 persons.

A part from local registration in some centres there is no national registry of PID in Egypt, and hence, the prevalence of these disorders in the investigator's population is still unknown .

An increasing number of PID are recognized, and effective treatments are possible. Early use of prophylactic antibiotics and replacement immunoglobulin can prevent significant end organ damage and improve long quality of life in these patients .

Immunoglobulin G (IgG) is an essential plasma derived medicine that is lacking in developing countries .IgG shortages leave immune deficient patients without treatment, exposing them to devastating recurrent infections from local pathogens. A simple and practical method for producing IgG from normal plasma collected in developing countries is needed to provide better, faster access to IgG for patients .

Magdy EL-Ekiaby, et al 2010 introduce the concept of small-scale ("minipool") plasma processing methods implementable with minimum infrastructural requirements. They developed viral inactivation and protein purification technologies in single-use equipment to prepare virally safe solvent/detergent-filtered (S/D-F) plasma Producing a 90%pure immunoglobulin fraction in disposable single-use devices for transfusion as well as minipool S/D-F cryoprecipitate to treat bleeding disorders.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Immunodeficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Single Group Assignment

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

minipooled- Intravenous immunoglobulin(MP-IVIG)

• MP-IVIG equivalent to 1 g/ kg of standard IVIG over a 6-hour to 8-hour period monthly alternated by standard IVIG for a period of 12 months follow up and the newly diagnosed cases admitted to AUH in the follow up period will be included.

Group Type EXPERIMENTAL

minipooled- Intravenous immunoglobulin(MP-IVIG)

Intervention Type OTHER

The process of MP-IVIG preparation will involve the use of caprylic acid for purification and virus inactivation of Igs from mini-pools of 20 plasma donations collected in our CBTS in AUH. The equipment used for the process comprised disposable blood bags, hemodialyzers, and purification and microbial filters.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

minipooled- Intravenous immunoglobulin(MP-IVIG)

The process of MP-IVIG preparation will involve the use of caprylic acid for purification and virus inactivation of Igs from mini-pools of 20 plasma donations collected in our CBTS in AUH. The equipment used for the process comprised disposable blood bags, hemodialyzers, and purification and microbial filters.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age group: children patients under 18 years.
* The study will include patient diagnosed as primary immunodeficiency disease (PID) in Assiut university hospital on standard IVIG therapy.

Exclusion Criteria

* Patient has SCID.
* Patient with history of severe IVIG side effect.
* Patient with severe immunodeficiency and has severe disseminated infection.
* Patient with renal impairment
* Patient with hepatic cell failure
* Patient with endocrinal abnormalities
* patient with secondary immunodeficiency diseases

Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No